Private Advisor Group’s Matinas BioPharma MTNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-463
Closed -$54.9K – 2481
2024
Q2
$54.9K Hold
463
– – ﹤0.01% 2267
2024
Q1
$94K Buy
463
+13
+3% +$2.32K ﹤0.01% 2206
2023
Q4
$72.9K Buy
450
+107
+31% +$18.1K ﹤0.01% 2144
2023
Q3
$33.5K Buy
343
+56
+20% +$10.3K ﹤0.01% 2064
2023
Q2
$77K Buy
287
+27
+10% +$9.44K ﹤0.01% 1945
2023
Q1
$91.8K Buy
260
+6
+2% +$2.27K ﹤0.01% 1874
2022
Q4
$25K Buy
254
+27
+12% +$13.5K ﹤0.01% 953
2022
Q3
$109K Sell
227
-80
-26% -$47.1K ﹤0.01% 1768
2022
Q2
$181K Sell
307
-12
-4% -$6.86K ﹤0.01% 1864
2022
Q1
$192K Buy
319
+119
+60% +$65.7K ﹤0.01% 1909
2021
Q4
$151K Sell
200
-95
-32% -$76.2K ﹤0.01% 1977
2021
Q3
$288K Buy
295
+137
+87% +$88.7K ﹤0.01% 1718
2021
Q2
$92K Sell
158
-24
-13% -$15.5K ﹤0.01% 1909
2021
Q1
$143K Buy
182
+29
+19% +$29.2K ﹤0.01% 1782
2020
Q4
$156K Sell
153
-30
-16% -$20.8K ﹤0.01% 1661
2020
Q3
$106K Hold
183
– – ﹤0.01% 1486
2020
Q2
$107K Buy
183
+41
+29% +$23.6K ﹤0.01% 1667
2020
Q1
$64K Buy
142
+51
+56% +$46.2K ﹤0.01% 1355
2019
Q4
$154K Sell
91
-9
-9% -$7.82K ﹤0.01% 1527
2019
Q3
$50K Buy
100
+20
+25% +$10.8K ﹤0.01% 1607
2019
Q2
$51K Buy
80
+13
+19% +$9.37K ﹤0.01% 1624
2019
Q1
$55K Buy
67
+1
+2% +$808 ﹤0.01% 1513
2018
Q4
$30K Buy
66
+33
+100% +$19.4K ﹤0.01% 1338
2018
Q3
$23K Buy
+33
New +$10.6K ﹤0.01% 1578
2018
Q2
– Sell
-23
Closed -$13K – 1391
2018
Q1
$13K Buy
+23
New +$18.2K ﹤0.01% 1143

Other funds holding MTNB

Private Advisor Group's MTNB Position: Q3 2024 in Review

Private Advisor Group sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 463 shares — an estimated $54.9K sold.

Private Advisor Group first reported a position in MTNB in Q1 2018 and held it in 25 quarters. The position peaked at $288K in Q3 2021. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

  • Private Advisor Group reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
  • Private Advisor Group sold 463 Matinas BioPharma shares in Q3 2024, an estimated $54.9K.
  • Private Advisor Group first reported a position in Matinas BioPharma in Q1 2018 and held it in 25 quarters.
  • Private Advisor Group's Matinas BioPharma position peaked at $288K in Q3 2021.
  • 18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Private Advisor Group's 13F filing for Q3 2024, filed 22 Oct 2024.